Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.

ABSTRACT:

Background and aims

Globally, NAFLD is one of the most common liver disorders, with an estimated prevalence rate of more than 30% in men and 15% in women and an even higher prevalence in people with type 2 diabetes mellitus. Optimal pharmacologic therapeutic approaches for NAFLD are an urgent necessity.

Approach and results

In this study, we showed that compared with healthy controls, hepatic ACSL4 levels in patients with NAFLD were found to be elevated. Suppression of ACSL4 expression promoted mitochondrial respiration, thereby enhancing the capacity of hepatocytes to mediate β-oxidation of fatty acids and to minimize lipid accumulation by up-regulating peroxisome proliferator-activated receptor coactivator-1 alpha. Moreover, we found that abemaciclib is a potent and select

SUBMITTER: Duan J 

PROVIDER: S-EPMC8688219 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature